Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin in advanced non-L soft-tissue sarcoma
NCT04008238Completed
- Sponsor
- Institut Bergonié
- Start
- Jan 2020
- Primary completion
- Aug 2024
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of trabectedin in soft tissue sarcoma (STS), sponsored by Institut Bergonié. Primary endpoint: Objective Response or Stable Disease > 6 months. Started Jan 2020; status: completed.
02
Drugs
trabectedin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT04008238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04008238.